SynthesisBMC cancer2026
Treatment outcomes of fruquintinib combined with PD-1 inhibitors in advanced colorectal cancer: a reconstructed patient-level meta-analysis of retrospective real-world studies.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFruquintinib is an established treatment option for patients with advanced colorectal cancer (CRC) who have progressed after standard therapies, including oxaliplatin- and irinotecan-based chemotherapy. Although this population generally shows limited sensitivity to anti-PD-1/PD-L1 immunotherapy, the combination of fruquintinib and PD-1 inhibitors has been widely used in clinical practice. In this reconstructed patient-level meta-analysis, we aimed to characterize survival outcomes reported in retrospective real-world studies evaluating fruquintinib combined with PD-1 inhibitors.
methodsPublic databases, including PubMed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), were systematically searched on January 26, 2026. Patient-level survival data were reconstructed from published Kaplan-Meier curves using the "IPDfromKM" package in R. The "survival" package was used to analyze reconstructed overall survival (OS) and progression-free survival (PFS). The "meta" package was used to pool objective response rate (ORR) and disease control rate (DCR).
resultsA total of 10 retrospective studies involving 609 patients were included, all conducted in China. The reported median OS ranged from 14.9 to 19.5 months, and the pooled median OS was 15.7 months. The reported median PFS ranged from 3.8 to 7.0 months, and the pooled median PFS was 5.5 months. The pooled ORR was 12% (95% CI, 7-18), and the pooled DCR was 74% (95% CI, 68-81). No significant publication bias was detected in the analyses of response rates.
conclusionThis reconstructed patient-level meta-analysis provides a descriptive summary of reported outcomes associated with fruquintinib combined with PD-1 inhibitors in patients with advanced CRC across retrospective real-world studies. However, safety outcomes were not systematically reported and therefore could not be comprehensively evaluated. Given the absence of a comparator group, the current evidence does not allow assessment of whether the addition of PD-1 inhibitors improves outcomes compared with fruquintinib monotherapy. Prospective randomized controlled trials are warranted to further characterize the clinical outcomes and safety profile of this treatment strategy.
Indexed as
Identifiers
42458329What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.